Amicus Therapeutics (FOLD) 16.76 $FOLD
Uptrend Call Working As Amicus Therapeutics Stock Rises 86.0% (FOLD)
Comtex SmarTrend(R) - Fri Jul 17, 9:49AM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on February 23rd, 2015 at $8.78. In approximately 5 months, Amicus Therapeutics has returned 85.99% as of today's recent price of $16.33.
FOLD: 16.76 (+0.16)
Can The Uptrend Continue for Amicus Therapeutics (FOLD)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 17, 7:31AM CDT
Can The Uptrend Continue for Amicus Therapeutics (FOLD)?
FOLD: 16.76 (+0.16)
5 Drugs That Investors May Be Undervaluing
Todd Campbell, The Motley Fool - Motley Fool - Mon Jul 13, 8:55AM CDT
Source: Flickr user stockmonkeys.com. Attaching a dollar value to a biotech stock's clinical trial pipeline is one -- if not the most -- vexing challenge facing biotech investors. The vast majority of drugs in human trials are destined for the...
GILD: 117.66 (+0.22), ACHN: 8.97 (-0.12), OPHT: 69.97 (-0.48), RCPT: 228.27 (-0.13), FOLD: 16.76 (+0.16)
60.5% Return Seen to Date on SmarTrend Amicus Therapeutics Call (FOLD)
Comtex SmarTrend(R) - Fri Jul 10, 9:18AM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on February 23rd, 2015 at $8.78. In approximately 5 months, Amicus Therapeutics has returned 60.48% as of today's recent price of $14.09.
FOLD: 16.76 (+0.16)
Why Shares in Amicus Therapeutics Shot Higher in June
Todd Campbell, The Motley Fool - Motley Fool - Sat Jul 04, 8:58AM CDT
Excitement following a filing for approval in Europe of Galafold, a treatment for Fabry disease, sent shares in Amicus Therapeutics surging 14.9% higher in June. The backstory If European regulators approve Galafold, it will compete against ...
FOLD: 16.76 (+0.16)
Amicus Therapeutics Up 56.6% Since SmarTrend Uptrend Call (FOLD)
Comtex SmarTrend(R) - Thu Jul 02, 4:47PM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on February 23rd, 2015 at $8.78. In approximately 4 months, Amicus Therapeutics has returned 56.61% as of today's recent price of $13.75.
FOLD: 16.76 (+0.16)
Pompe Disease - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d3wrwn/pompe_disease) has announced the addition of the "Pompe Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pompe Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pompe Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Amicus Therapeutics, Inc. - Audentes Therapeutics, Inc. - BioMarin Pharmaceutical Inc. - Cortex Pharmaceuticals, Inc. - EpiVax, Inc. - Genzyme Corporation - Oxyrane Belgium NV - Pharming Group N.V. - Sarepta Therapeutics, Inc. - Synageva BioPharma Corp. For more information visit http://www.researchandmarkets.com/research/d3...pe_disease
GEVA: 238.60 (+2.80), BMRN: 148.05 (+4.05), SRPT: 33.35 (-0.31), FOLD: 16.76 (+0.16)
Global Pompe Disease Market 2015-2019 - Special Provisions for Orphan Drugs
M2 - Mon Jun 29, 6:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rknz4b/global_pompe) has announced the addition of the "Global Pompe Disease Market 2015-2019" report to their offering. The analysts forecast the Global Pompe Disease market to grow at a CAGR of 11.79 percent over the period 2014-2019. Pompe disease affects both men and women, irrespective of the gender. Pompe disease affects people across all ethnicities and races. Individuals affected with Pompe disease acquire the disease at birth, however, the onset of symptoms varies extensively. More than 300 genetic mutations that can cause Pompe disease have been identified by the researchers till date. Though there is no cure for Pompe disease, diet therapy and enzyme replacement therapy are effective in reducing the clinical manifestations of the disease. Increased awareness has made regulatory authorities work steadily toward developing guidelines and providing assistance to drug manufacturers to promote R&D of drugs to treat the disease. Emerging economies are rapidly becoming aware of the importance of orphan drug designations and are working toward the development of regulatory protocols required to award these designations. According to the report, special provisions allocated to drugs for orphan diseases have a positive impact on market growth. Incentives in the form of funding, guidance, and marketing exclusivity provide attractive opportunities to vendors to conduct research in this disease area. For instance, the drug Myozyme was designated as an orphan drug by the FDA in 1997. Further, the report states that a limited patient population hinders the effective evaluation of drugs based on clinical trials. The presence of few affected people has a negative impact on drug sales and prolongs the time period by which a vendor can recover the R&D expenses of the drug. Key Vendors - Amicus Therapeutics - BioMarin Pharmaceutical - Genzyme Other Prominent Vendors - Audentes Therapeutics - EpiVax - Oxyrane - Sangamo BioSciences - Valerion Therapeutics Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Disease Overview - Market Landscape - Pipeline Analysis - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/rk...obal_pompe
BMRN: 148.05 (+4.05), SGMO: 8.83 (-0.77), FOLD: 16.76 (+0.16)
Amicus Therapeutics Joins Russell 3000(R) and Russell 2000(R) Indexes
GlobeNewswire - Mon Jun 29, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, has been added to the U.S. broad-market Russell 3000(R) and small-cap Russell 2000(R) Indexes. The Company joined the indexes at the close of market on Friday, June 26, 2015, when Russell Investments reconstituted its U.S. and global equity indexes.
FOLD: 16.76 (+0.16)
SmarTrend Watching for Potential Pullback in Shares of Amicus Therapeutics After 2.86% Gain
Comtex SmarTrend(R) - Fri Jun 26, 4:48PM CDT
Amicus Therapeutics (NASDAQ:FOLD) traded in a range yesterday that spanned from a low of $13.50 to a high of $14.65. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $14.23 on volume of 13.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
FOLD: 16.76 (+0.16)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jun 25, 4:35PM CDT
BLUE: 163.54 (+1.54), VRTX: 130.85 (-0.17), BIDU: 207.63 (+1.89), MRVL: 12.42 (+0.02), CALA: 8.06 (-0.32), WDC: 77.90 (-0.62), CAFD: 16.82 (+0.01), FOLD: 16.76 (+0.16), EXEL: 5.88 (-0.43), STRZA: 44.44 (-0.84)
EMA accepts Amicus' MAA for migalastat for Fabry
Seeking Alpha - at Seeking Alpha - Thu Jun 25, 3:56PM CDT
SHPG: 261.24 (+1.78), SNY: 53.37 (+0.28), FOLD: 16.76 (+0.16)
Amicus Therapeutics Announces Galafold(TM) Marketing Authorization Application (MAA) Validated by European Medicines Agency (EMA)
GlobeNewswire - Thu Jun 25, 3:01PM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) and the Centralized Procedure has begun for the oral small molecule pharmacological chaperone Galafold (migalastat HCl) for Fabry patients who have amenable genetic mutations. As previously announced, Galafold is the first investigational Fabry drug to be granted Accelerated Assessment in the EU. In the U.S., Amicus plans to conduct a pre-NDA meeting with the FDA and to submit a New Drug Application (NDA) for Galafold under Subpart H in the second half of 2015. Following the MAA validation, Amicus is also initiating the regulatory submission process in several additional geographies.
FOLD: 16.76 (+0.16)
Shares of FOLD Up 53.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 25, 11:24AM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on February 23rd, 2015 at $8.78. In approximately 4 months, Amicus Therapeutics has returned 53.76% as of today's recent price of $13.50.
FOLD: 16.76 (+0.16)
BUYINS.NET: CENTA, GAF, GMM, FOLD, PPO, ZINC Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Jun 24, 7:18AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Central Garden & Pet Co (NASDAQ:CENTA), SPDR S&P Emerging Middle East & Africa ETF (NYSE:GAF), SPDR S&P Emerging Markets ETF (NYSE:GMM), Amicus Therapeutics Inc (NASDAQ:FOLD), Polypore International Inc (NYSE
PO), HORSEHEAD HOLDING CORPORATION (NASDAQ:ZINC) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
ZINC: 8.19 (+0.35), GAF: 65.81 (+0.06), PPO: 60.02 (-0.07), CENTA: 10.60 (-0.20), GMM: 61.43 (-0.62), FOLD: 16.76 (+0.16)
Is There Further Upside In Amicus Therapeutics?
Emerging Equities - at Seeking Alpha - Mon Jun 22, 1:43PM CDT
FOLD: 16.76 (+0.16)
Amicus Therapeutics Has Returned 53.8% Since SmarTrend Recommendation (FOLD)
Comtex SmarTrend(R) - Thu Jun 18, 9:47AM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on February 23rd, 2015 at $8.78. In approximately 4 months, Amicus Therapeutics has returned 53.76% as of today's recent price of $13.50.
FOLD: 16.76 (+0.16)
Amicus Therapeutics concludes public offering of 19.53m common shares
M2 - Thu Jun 18, 3:00AM CDT
Biopharmaceutical company Amicus Therapeutics (NasdaqGM:FOLD) disclosed on Wednesday the completion of its public offering of 19,528,302 shares of its common stock.
FOLD: 16.76 (+0.16)
Uptrend Call Working As Amicus Therapeutics Stock Rises 86.0% (FOLD)
Comtex SmarTrend(R) - Fri Jul 17, 9:49AM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on February 23rd, 2015 at $8.78. In approximately 5 months, Amicus Therapeutics has returned 85.99% as of today's recent price of $16.33.
FOLD: 16.76 (+0.16)
Can The Uptrend Continue for Amicus Therapeutics (FOLD)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 17, 7:31AM CDT
Can The Uptrend Continue for Amicus Therapeutics (FOLD)?
FOLD: 16.76 (+0.16)
5 Drugs That Investors May Be Undervaluing
Todd Campbell, The Motley Fool - Motley Fool - Mon Jul 13, 8:55AM CDT
Source: Flickr user stockmonkeys.com. Attaching a dollar value to a biotech stock's clinical trial pipeline is one -- if not the most -- vexing challenge facing biotech investors. The vast majority of drugs in human trials are destined for the...
GILD: 117.66 (+0.22), ACHN: 8.97 (-0.12), OPHT: 69.97 (-0.48), RCPT: 228.27 (-0.13), FOLD: 16.76 (+0.16)
60.5% Return Seen to Date on SmarTrend Amicus Therapeutics Call (FOLD)
Comtex SmarTrend(R) - Fri Jul 10, 9:18AM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on February 23rd, 2015 at $8.78. In approximately 5 months, Amicus Therapeutics has returned 60.48% as of today's recent price of $14.09.
FOLD: 16.76 (+0.16)
Why Shares in Amicus Therapeutics Shot Higher in June
Todd Campbell, The Motley Fool - Motley Fool - Sat Jul 04, 8:58AM CDT
Excitement following a filing for approval in Europe of Galafold, a treatment for Fabry disease, sent shares in Amicus Therapeutics surging 14.9% higher in June. The backstory If European regulators approve Galafold, it will compete against ...
FOLD: 16.76 (+0.16)
Amicus Therapeutics Up 56.6% Since SmarTrend Uptrend Call (FOLD)
Comtex SmarTrend(R) - Thu Jul 02, 4:47PM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on February 23rd, 2015 at $8.78. In approximately 4 months, Amicus Therapeutics has returned 56.61% as of today's recent price of $13.75.
FOLD: 16.76 (+0.16)
Pompe Disease - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d3wrwn/pompe_disease) has announced the addition of the "Pompe Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pompe Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pompe Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Amicus Therapeutics, Inc. - Audentes Therapeutics, Inc. - BioMarin Pharmaceutical Inc. - Cortex Pharmaceuticals, Inc. - EpiVax, Inc. - Genzyme Corporation - Oxyrane Belgium NV - Pharming Group N.V. - Sarepta Therapeutics, Inc. - Synageva BioPharma Corp. For more information visit http://www.researchandmarkets.com/research/d3...pe_disease
GEVA: 238.60 (+2.80), BMRN: 148.05 (+4.05), SRPT: 33.35 (-0.31), FOLD: 16.76 (+0.16)
Global Pompe Disease Market 2015-2019 - Special Provisions for Orphan Drugs
M2 - Mon Jun 29, 6:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rknz4b/global_pompe) has announced the addition of the "Global Pompe Disease Market 2015-2019" report to their offering. The analysts forecast the Global Pompe Disease market to grow at a CAGR of 11.79 percent over the period 2014-2019. Pompe disease affects both men and women, irrespective of the gender. Pompe disease affects people across all ethnicities and races. Individuals affected with Pompe disease acquire the disease at birth, however, the onset of symptoms varies extensively. More than 300 genetic mutations that can cause Pompe disease have been identified by the researchers till date. Though there is no cure for Pompe disease, diet therapy and enzyme replacement therapy are effective in reducing the clinical manifestations of the disease. Increased awareness has made regulatory authorities work steadily toward developing guidelines and providing assistance to drug manufacturers to promote R&D of drugs to treat the disease. Emerging economies are rapidly becoming aware of the importance of orphan drug designations and are working toward the development of regulatory protocols required to award these designations. According to the report, special provisions allocated to drugs for orphan diseases have a positive impact on market growth. Incentives in the form of funding, guidance, and marketing exclusivity provide attractive opportunities to vendors to conduct research in this disease area. For instance, the drug Myozyme was designated as an orphan drug by the FDA in 1997. Further, the report states that a limited patient population hinders the effective evaluation of drugs based on clinical trials. The presence of few affected people has a negative impact on drug sales and prolongs the time period by which a vendor can recover the R&D expenses of the drug. Key Vendors - Amicus Therapeutics - BioMarin Pharmaceutical - Genzyme Other Prominent Vendors - Audentes Therapeutics - EpiVax - Oxyrane - Sangamo BioSciences - Valerion Therapeutics Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Disease Overview - Market Landscape - Pipeline Analysis - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/rk...obal_pompe
BMRN: 148.05 (+4.05), SGMO: 8.83 (-0.77), FOLD: 16.76 (+0.16)
Amicus Therapeutics Joins Russell 3000(R) and Russell 2000(R) Indexes
GlobeNewswire - Mon Jun 29, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, has been added to the U.S. broad-market Russell 3000(R) and small-cap Russell 2000(R) Indexes. The Company joined the indexes at the close of market on Friday, June 26, 2015, when Russell Investments reconstituted its U.S. and global equity indexes.
FOLD: 16.76 (+0.16)
SmarTrend Watching for Potential Pullback in Shares of Amicus Therapeutics After 2.86% Gain
Comtex SmarTrend(R) - Fri Jun 26, 4:48PM CDT
Amicus Therapeutics (NASDAQ:FOLD) traded in a range yesterday that spanned from a low of $13.50 to a high of $14.65. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $14.23 on volume of 13.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
FOLD: 16.76 (+0.16)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jun 25, 4:35PM CDT
BLUE: 163.54 (+1.54), VRTX: 130.85 (-0.17), BIDU: 207.63 (+1.89), MRVL: 12.42 (+0.02), CALA: 8.06 (-0.32), WDC: 77.90 (-0.62), CAFD: 16.82 (+0.01), FOLD: 16.76 (+0.16), EXEL: 5.88 (-0.43), STRZA: 44.44 (-0.84)
EMA accepts Amicus' MAA for migalastat for Fabry
Seeking Alpha - at Seeking Alpha - Thu Jun 25, 3:56PM CDT
SHPG: 261.24 (+1.78), SNY: 53.37 (+0.28), FOLD: 16.76 (+0.16)
Amicus Therapeutics Announces Galafold(TM) Marketing Authorization Application (MAA) Validated by European Medicines Agency (EMA)
GlobeNewswire - Thu Jun 25, 3:01PM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) and the Centralized Procedure has begun for the oral small molecule pharmacological chaperone Galafold (migalastat HCl) for Fabry patients who have amenable genetic mutations. As previously announced, Galafold is the first investigational Fabry drug to be granted Accelerated Assessment in the EU. In the U.S., Amicus plans to conduct a pre-NDA meeting with the FDA and to submit a New Drug Application (NDA) for Galafold under Subpart H in the second half of 2015. Following the MAA validation, Amicus is also initiating the regulatory submission process in several additional geographies.
FOLD: 16.76 (+0.16)
Shares of FOLD Up 53.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 25, 11:24AM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on February 23rd, 2015 at $8.78. In approximately 4 months, Amicus Therapeutics has returned 53.76% as of today's recent price of $13.50.
FOLD: 16.76 (+0.16)
BUYINS.NET: CENTA, GAF, GMM, FOLD, PPO, ZINC Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Jun 24, 7:18AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Central Garden & Pet Co (NASDAQ:CENTA), SPDR S&P Emerging Middle East & Africa ETF (NYSE:GAF), SPDR S&P Emerging Markets ETF (NYSE:GMM), Amicus Therapeutics Inc (NASDAQ:FOLD), Polypore International Inc (NYSE
PO), HORSEHEAD HOLDING CORPORATION (NASDAQ:ZINC) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: ZINC: 8.19 (+0.35), GAF: 65.81 (+0.06), PPO: 60.02 (-0.07), CENTA: 10.60 (-0.20), GMM: 61.43 (-0.62), FOLD: 16.76 (+0.16)
Is There Further Upside In Amicus Therapeutics?
Emerging Equities - at Seeking Alpha - Mon Jun 22, 1:43PM CDT
FOLD: 16.76 (+0.16)
Amicus Therapeutics Has Returned 53.8% Since SmarTrend Recommendation (FOLD)
Comtex SmarTrend(R) - Thu Jun 18, 9:47AM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on February 23rd, 2015 at $8.78. In approximately 4 months, Amicus Therapeutics has returned 53.76% as of today's recent price of $13.50.
FOLD: 16.76 (+0.16)
Amicus Therapeutics concludes public offering of 19.53m common shares
M2 - Thu Jun 18, 3:00AM CDT
Biopharmaceutical company Amicus Therapeutics (NasdaqGM:FOLD) disclosed on Wednesday the completion of its public offering of 19,528,302 shares of its common stock.
FOLD: 16.76 (+0.16)
